- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03669133
Vitamin E for NASH Treatment in HIV Infected Individuals
Study Overview
Status
Intervention / Treatment
Detailed Description
The investigators will conduct a proof-of-concept clinical trial to evaluate the efficacy of vitamin E for treatment of non-alcoholic steatohepatitis (NASH) in persons living with HIV. Hypothesis: Vitamin E will improve radiographically measured hepatic fat content and circulating markers of liver inflammation and injury in persons living with HIV who have NASH.
A. Perform a pilot randomized placebo controlled trial of vitamin E 800 IU/daily for 6 months in 56 persons living with HIV with biopsy-proven NASH B. Measure change in liver fat content by magnetic resonance proton-density fat fraction (Primary outcome) C. Determine the impact of vitamin E treatment on noninvasive markers of hepatic and systemic inflammation, hepatic fibrosis, and systemic oxidative stress (Secondary outcomes) D. Define baseline hepatic gene expression signatures predictive of response to therapy.
Upon completion, the proposed clinical trial may establish vitamin E as an excellent and inexpensive candidate for further development as a treatment for NASH in persons living with HIV.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- males and females ≥18 years with biopsy-proven NASH within 6 months prior to enrollment
- histological diagnosis of NASH will be confirmed by an experienced liver pathologist before study entry
- HIV infection
- stable dose of anti-diabetic agents and ART in the 3 months preceding enrollment and expected by the physician treating diabetes and HIV to remain on stable medications during the study
- willingness to participate in the study
- ability to understand and give informed consent for participation
Exclusion Criteria:
- Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis, cholestatic liver disease, Wilson disease, hemochromatosis, etc.)
- average alcohol consumption >3 drinks/day for men or >2 drinks/day for women in the 6 months prior to enrollment.
- Alcohol Use Disorder Identification Test (AUDIT) score of ≥8
- evidence of cirrhosis on histology or imaging
- ongoing use of medications known to cause hepatic steatosis (e.g., corticosteroids, amiodarone, methotrexate, tetracycline, tamoxifen, estrogens at doses greater than those used for birth control, anabolic steroids, or valproic acid)
- prior bariatric surgery
- severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric illness)
- allergy to vitamin E
- use of vitamin E or multivitamins containing vitamin E in the three months preceding enrollment
- use of drugs with potential effect on NASH such as ursodeoxycholic acid, S-adenosylmethionine (SAM-e), betaine, pentoxifylline, or milk thistle in the three months prior to enrollment.
- changing doses of statins (simvastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the three months prior enrollment.
- illicit substance abuse within the past twelve months
- breast feeding, pregnancy, inability or unwillingness to practice contraception for the duration of the study
- contraindications for the MRI procedure (e.g., prostheses, severe claustrophobia)
- poorly controlled diabetes with A1C >8.5 within in the last six months
- use of total parenteral nutrition in the 6 months preceding liver biopsy or enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A
Vitamin E 800 IU/daily for 24 weeks
|
Vitamin E 800 IU/daily
|
Placebo Comparator: Group B
Matching placebo for 24 weeks
|
Matching placebo daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Liver Fat Content by Magnetic Resonance Proton-Density Fat Fraction
Time Frame: at randomization visit (study day 1) and end of study visit (week 24)
|
change in liver steatosis via MRI-PDFF at randomization (day 1) and study completion (week 24) to assess liver steatosis
|
at randomization visit (study day 1) and end of study visit (week 24)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of Vitamin E Treatment on Noninvasive Markers of Hepatic Fibrosis
Time Frame: change from baseline (first screening visit) to the end of study visit (week 24)
|
This outcome measure reflects the change in liver stiffness in transient elastrography via FibroScan is measured in (kPa) for study participants at two study time points
|
change from baseline (first screening visit) to the end of study visit (week 24)
|
Impact of Treatment on ALT as a Noninvasive Marker of Hepatic Inflammation
Time Frame: at randomization visit (study day 1) and end of study visit (week 24)
|
This measure reflects the change in ALT(IU/L) value for study participants at two study time points
|
at randomization visit (study day 1) and end of study visit (week 24)
|
Impact of Treatment on AST as a Noninvasive Marker of Hepatic Inflammation
Time Frame: Change in AST from study randomization (day 1) through the end of study visit (week 24)
|
This measure reflects the change in AST(IU/L) value for study participants at two study time points
|
Change in AST from study randomization (day 1) through the end of study visit (week 24)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1807274844
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Vitamin E
-
National Institute of Diabetes and Digestive and...Completed
-
Hospital General Universitario ElcheCompleted
-
Shiraz University of Medical SciencesCompletedRestless Legs Syndrome | Kidney Failure, ChronicIran, Islamic Republic of
-
Aesculap AGRaylytic GmbH; B. Braun Medical FranceRecruitingArthritis, Rheumatoid | Osteoarthritis, Knee | Joint Instability | Intra-Articular Fractures | Genu Valgum or VarumFrance, Germany
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedChronic Arsenic PoisoningBangladesh
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedBreast Cancer | FatigueUnited States
-
University of Health Sciences LahoreCompleted
-
Hospital General Universitario ElcheCompletedSurgical Site Infection
-
University Hospital, GenevaCompleted